Press Releases

BETHESDA, MD, May 1, 2015 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the Company has closed on the $28.5 million second tranche of a $40 million investment from Woodford investment funds in the UK (“Woodford”). Woodford first invested $25 million in NW Bio on November 19, 2014.  On April 2, 2015,... Read More

DCVax-L and DCVax-Direct Both To Be the Subject of Presentations Today  BETHESDA, MD, April 20, 2015 — Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that its clinical programs with DCVax-L for Glioblastoma multiforme (GBM) brain cancer, and with DCVax-Direct for all types of inoperable solid tumors, will be featured in... Read More

NW Bio Currently Ranked 8th Among the 25 Companies  BETHESDA, MD, April 16, 2015 – Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) (“NW Bio”), a biotechnology company developing non-toxic DCVax® personalized immune therapies for cancer, announced today that it has been included in the Loncar Cancer Immunotherapy Index (LCINDX), a professional index recently established to help investors better track the immunotherapy field within the... Read More

BETHESDA, MD, April 9, 2015 – Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) (“NW Bio”), a biotechnology company developing non-toxic DCVax® personalized immune therapies for cancer, announced today that Leslie J. Goldman, Senior Vice President Business Development, will present at the World Vaccine Congress 2015 that is being held in Washington, DC from April 7- 9. Mr. Goldman will be speaking as part of the co-located Cancer &... Read More

Further Equity Investment By Woodford Funds BETHESDA, MD, April 2, 2015 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that today the Company entered into agreement with Woodford Investment Management LLP (“Woodford”), as agent for the CF Woodford Equity Income Fund and other clients, for financing of $40 million.... Read More